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The ischaemic cascade
Coronary artery disease (CAD) is primarily a structural disease char-
acterized by the build-up of atherosclerotic plaques in the coronary
arteries. With progressive impingement on coronary blood flow, a
given coronary stenosis will elicit functional consequences that are
described by the ‘ischaemic cascade’ and emerge progressively as in-
ducible changes of perfusion, wall motion, and electrocardiogram,
and finally manifest as chest pain (Figure 1). Thus, definitions for clin-
ically significantCADmayvary considerably basedonwhether rather
anatomical vs. functional criteria are used (Table 1).
Paradigms of cardiac imaging
Soon after F Mason Sones seminal first angiography on 30 October
1958 in theCardiac Laboratories of the ClevelandClinic, the diagno-
sis of CAD was largely based on angiographical documentation of
coronary stenoses. The term ‘significant CAD’ was defined by the
presence of coronary stenoses exceeding a certain threshold of
luminal diameter narrowing (50 or 70%).1 Over the last three
decades; however, several non-invasive techniques have been devel-
oped, validated, and widely accepted for the diagnosis of CAD. They
include stress-echocardiography (stress-echo), single photon emis-
sion computed tomography (SPECT), positron emission tomog-
raphy (PET), cardiac magnetic resonance (CMR), and CT coronary
angiography (CTCA). Except forCTCA, themajority of non-invasive
techniques is aiming at detecting myocardial perfusion abnormalities
caused by coronary stenoses, by either assessing the regional distri-
bution of ‘contrast agents’ throughout the left ventricular myocar-
dium or changes in regional wall motion during conditions of stress
or hyperaemia. In the 1990s, fractional flow reserve (FFR) was devel-
oped as a way of assessing the functional significance of a given cor-
onary stenosis during invasive angiography using an intracoronary
pressure wire. To establish its value as a functional test that would
predict myocardial ischaemia, FFR was validated in several studies
against the non-invasive functional tests that were more established
at that time, predominantly SPECT or stress-echo.
Confused at a higher level
It is one of the most fundamental—albeit unexpected—realities in
CAD that the agreement between anatomical (i.e. degree of coron-
ary stenosis) and functional (i.e. myocardial perfusion) aspects is
poor.2–7 In other words, a given diameter narrowing of 60% in a cor-
onary arterymay be haemodynamically relevant in patient A, while in
patient B the same stenosis is not flow-limiting. The reason for this
variability is summarized in Figure 2 and relates to the fact that myo-
cardial blood flow is determined bymanyother factors besides diam-
eter stenosis which are poorly appraised by conventional
angiography. Hence, a perfect agreement between functional tests
of myocardial ischaemia and angiographical gold standards of coron-
ary artery structure is by nature impossible, since different aspects of
CAD are visualized. And yet, ironically, the majority of non-invasive
tests havebeen validated against conventionalCAclaiming the super-
iority of one or the othermodality, if a higher diagnostic accuracywas
obtained against the gold standard of invasive angiography.8–11
From imaging to clinical impact
In search of an appropriate definition for CAD, one should consider
those nosological features that will have an impact on the patient’s
prognosis and therefore guide treatment. Several large-scale follow-
up studies have demonstrated thatmyocardial ischaemia as detected
by non-invasive functional testing is one of the strongest predictors
of outcome in stable CAD patients, regardless of whether it is
causedbya50%ora70%coronary artery stenosis.12–14Accordingly,
the concept of ischaemia-guided coronary revascularization has
emerged.15,16 The FAME I trial has strengthened this concept by
demonstrating that an ischaemia (FFR)-guided revascularization
strategy improves patients’ outcomes compared with an angiography-
guided strategy.17 Finally, the FAME II trial has proved—for the first
time in a prospective randomized setting—the superiority of re-
vascularization over optimal medical treatment for patients with
flow-limiting coronary stenoses (FFR,0.80).18 Accordingly, the def-
inition of clinically relevant CADhas shifted from significant stenoses
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
* Corresponding author. Tel: +41 44 255 10 52, Fax: +41 44 255 4414, Email: oliver.gaemperli@usz.ch
Published on behalf of the European Society of Cardiology. All rights reserved.& The Author 2013. For permissions please email: journals.permissions@oup.com
European Heart Journal (2013) 34, 2432–2435
doi:10.1093/eurheartj/eht170
Downloaded from https://academic.oup.com/eurheartj/article-abstract/34/31/2432/456868
by University of Zurich user
on 06 August 2018
(defined as % luminal narrowing) to haemodynamically relevant sten-
osis (as reflected by ischaemia on non-invasive imaging or a reduction
in the FFR value at angiography).
Coronary arteries and the
microcirculation
However, several areas of uncertainty remain: It is still unclear how
FFRcompareswith functional imaging techniques and somehave sug-
gested considerable disagreement.19,20 Fractional flow reserve does
not account for alterations ofmicrovascular or endothelial vasoreac-
tivity which may contribute to myocardial ischaemia under certain
conditions and influence prognosis (Table 1).21,22 For instance, in
the presence of severe microvascular dysfunction, FFR values
across a given coronary stenosis following adenosine-induced hyper-
aemia may be blunted. This could result in an underestimation of
pathophysiological severity of epicardial coronary disease, while at
the same time myocardial blood flow could be markedly reduced
thereby contributing to myocardial ischaemia and impaired progno-
sis (Figure 3).22 Conversely, relatively healthy subjects with marked
hyperaemic microvascular vasodilation may exhibit borderline FFR
values slightly ,0.80 across a given stenosis, despite preserved
hyperaemic myocardial blood flow. This is why early validation
studiesof FFRperformed in relatively ‘healthy’ subjectswith predom-
inantly one-vessel disease found the ideal cut-off for predicting
Figure 1 The ischaemic cascade: this concept assumes that with an increasing mismatch between coronary blood flow and myocardial oxygen
demand, coronary stenoses will elicit functional consequences in the supplied myocardium, i.e. changes of perfusion, diastolic or systolic wall
motion, electrocardiogram, and finally manifest as chest pain.
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Table 1 Semantics of coronary artery disease and
optimal diagnostic testing
Definition of CAD Optimal diagnostic test
Endothelial or
microvascular
dysfunction
Absolute flow quantification with PET,
physiological ICA studies (e.g.
acetylcholine)
(Epicardial) coronary
atherosclerosis
CTCA, ICA (with or without
intravascular imaging, i.e. IVUS, OCT)
Ischaemic heart disease SPECT, PET, S-Echo, perfusionCMR, ICA
with FFR
CAD, coronary artery disease; PET, positron emission tomography; ICA, invasive
coronary angiography; CTCA, CT coronary angiography; IVUS, intravascular
ultrasound; OCT, optical coherence tomography; SPECT, single photon emission
computed tomography; S-Echo, stress-echocardiography; CMR, cardiac magnetic
resonance; FFR, fractional flow reserve.
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Figure 2 Myocardial blood flow is determined by a variety of factors that affect the epicardial coronary compartment (A) or the microvascular
compartment (B). The epicardial coronary compartment is generally affected by coronary atherosclerosis obstructing conductive blood flow (A).
However, besides the angiographical severity of diameter narrowing, several other factors that are not or only poorly captured by invasive angiog-
raphy can modulate the haemodynamic relevance of a given lesion. (B) However, under resting conditions, 90% of coronary vascular resistance
resides in the microcirculation (arterioles and pre-arterioles). Microvascular dilation in response to various stressors is crucial to match blood
flow with myocardial oxygen demands. This regulation of microvascular resistance can be disturbed in the presence of a variety of functional or
structural pathologies and thereby contribute to myocardial ischaemia.
Figure 3 Comparison of fractional flow reserve vs. Non-invasive imaging modalities. Fractional flow reserve assesses only the pressure gradient
across a lesion in the epicardial coronary arteries. However, ischaemia bymyocardial perfusion imaging is an integratedmeasurement of blood flow
through the epicardial and microvascular compartement and, therefore, can also be affected by microvascular or endothelial dysfunction.
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myocardial ischaemia to be in the range of 0.72–0.75, i.e. consider-
ably lower than the currently accepted cut-off of 0.80.20
From pictures to outcome
All of the above have important implications for the design of future
imaging studies: at present, there is considerable discussion which of
the available imaging techniques is most accurate to diagnose CAD,
and a number of comparisons using CA as the gold standard have
been conducted and employed to prove the superiority of one tech-
niqueover theother.However, given the changing paradigmofCAD,
this approach appears outdated. Additionally, one should also realize
that perfusion and systolic function asmarkers of ischaemiamay rep-
resent different phenomena and may therefore not be directly com-
parable. Consequently, trials are needed that are designed to
demonstrate that non-invasive imaging can guide treatment and sub-
sequently improve patients’ outcome. Such trials may follow the
design of the FAME I and II trials and thereby continue the exemplary
path that FFR has set in invasive cardiology.17,18 Accordingly, efforts
across countries are currently joined to design appropriately sized
prospective randomized trials to test this hypothesis.23 In an era of
ever increasing pressure from financial reimbursement systems
such trials are eagerly needed to solidify the role of non-invasive
cardiac imaging in cardiology. By these means, clinical validation of
established or novel cardiac imaging techniques will centre around
the ultimate and most important gold standard in cardiology: guid-
ance of therapy aiming at improvement of patients’ outcome.
Conflict of interest: none declared.
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